Antibiotics

A mixture of Spiramycin I, II and III.

Spiramycin I is an antibiotic substance classified in the erythromycin-carbomycin group.

Spiramycin I is an antibiotic substance classified in the erythromycin-carbomycin group.

Spiramycin I is an antibiotic substance classified in the erythromycin-carbomycin group.

Spiramycin I is an antibiotic substance classified in the erythromycin-carbomycin group.

Spiramycin I-d3 is an antibiotic substance classified in the erythromycin-carbomycin group.Spiramycin I-d3is an antibiotic substance.

SPR206 acetate is a polymyxin analog with antibiotic activity against Gram-negative pathogens , including multidrug-resistant (MDR) variants. SPR206 acetate has an anti-bacterial infection effect by interacting with the bacterium’s outer membrane.

SPR206 acetate is a polymyxin analog with antibiotic activity against Gram-negative pathogens , including multidrug-resistant (MDR) variants. SPR206 acetate has an anti-bacterial infection effect by interacting with the bacterium’s outer membrane.

SPR206 acetate is a polymyxin analog with antibiotic activity against Gram-negative pathogens , including multidrug-resistant (MDR) variants. SPR206 acetate has an anti-bacterial infection effect by interacting with the bacterium’s outer membrane.

SPR741 acetate (NAB741 acetate) is a cationic peptide derived from polymyxin B and is a potentiator molecule. SPR741 acetate increases the permeability of the outer membrane of Gram-negative bacteria and is used to treat severe Gram-negative

SPR741 acetate (NAB741 acetate) is a cationic peptide derived from polymyxin B and is a potentiator molecule. SPR741 acetate increases the permeability of the outer membrane of Gram-negative bacteria and is used to treat severe Gram-negative

SPR741 acetate (NAB741 acetate) is a cationic peptide derived from polymyxin B and is a potentiator molecule. SPR741 acetate increases the permeability of the outer membrane of Gram-negative bacteria and is used to treat severe Gram-negative